AU2021391493C1 - Il-7 binding proteins and their use in medical therapy - Google Patents

Il-7 binding proteins and their use in medical therapy

Info

Publication number
AU2021391493C1
AU2021391493C1 AU2021391493A AU2021391493A AU2021391493C1 AU 2021391493 C1 AU2021391493 C1 AU 2021391493C1 AU 2021391493 A AU2021391493 A AU 2021391493A AU 2021391493 A AU2021391493 A AU 2021391493A AU 2021391493 C1 AU2021391493 C1 AU 2021391493C1
Authority
AU
Australia
Prior art keywords
binding protein
seq
acid sequence
amino acid
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021391493A
Other languages
English (en)
Other versions
AU2021391493A1 (en
AU2021391493A9 (en
AU2021391493B2 (en
Inventor
Gerben BOUMA
Edward Thomas COULSTOCK
David Dixon
Stephanie HOPLEY
Alan Peter Lewis
Jessica Lynn NEISEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2021391493A1 publication Critical patent/AU2021391493A1/en
Publication of AU2021391493A9 publication Critical patent/AU2021391493A9/en
Application granted granted Critical
Publication of AU2021391493B2 publication Critical patent/AU2021391493B2/en
Publication of AU2021391493C1 publication Critical patent/AU2021391493C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021391493A 2020-12-02 2021-11-30 Il-7 binding proteins and their use in medical therapy Active AU2021391493C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063120564P 2020-12-02 2020-12-02
US63/120,564 2020-12-02
PCT/EP2021/083465 WO2022117526A1 (en) 2020-12-02 2021-11-30 Il-7 binding proteins and their use in medical therapy

Publications (4)

Publication Number Publication Date
AU2021391493A1 AU2021391493A1 (en) 2023-06-08
AU2021391493A9 AU2021391493A9 (en) 2024-05-23
AU2021391493B2 AU2021391493B2 (en) 2025-10-30
AU2021391493C1 true AU2021391493C1 (en) 2026-04-16

Family

ID=78844686

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021391493A Active AU2021391493C1 (en) 2020-12-02 2021-11-30 Il-7 binding proteins and their use in medical therapy

Country Status (15)

Country Link
US (3) US11802150B2 (https=)
EP (1) EP4255928A1 (https=)
JP (1) JP2023551935A (https=)
KR (1) KR20230098288A (https=)
CN (1) CN116547002A (https=)
AR (1) AR124286A1 (https=)
AU (1) AU2021391493C1 (https=)
CA (1) CA3199648A1 (https=)
CL (1) CL2023001556A1 (https=)
CO (1) CO2023007851A2 (https=)
IL (1) IL303134A (https=)
MX (1) MX2023006294A (https=)
PH (1) PH12023551170A1 (https=)
TW (1) TWI821804B (https=)
WO (1) WO2022117526A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023227641A1 (en) * 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
US8961967B2 (en) * 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN ZHENLONG ET AL: "The Novel Role of IL-7 Ligation to IL-7 Receptor in Myeloid Cells of Rheumatoid Arthritis and Collagen-Induced Arthritis", THE JOURNAL OF IMMUNOLOGY, 2013, vol. 190, no. 10, pages 5256 - 5266 *
DOOMS HANS: "Interleukin-7: Fuel for the autoimmune attack", JOURNAL OF AUTOIMMUNITY, LONDON, GB, vol. 45, 4 July 2013 (2013-07-04), GB, pages 40 - 48, XP028718883, ISSN: 0896-8411, DOI: 10.1016/j.jaut.2013.06.007 *

Also Published As

Publication number Publication date
JP2023551935A (ja) 2023-12-13
CN116547002A (zh) 2023-08-04
AU2021391493A1 (en) 2023-06-08
IL303134A (en) 2023-07-01
US11802150B2 (en) 2023-10-31
AU2021391493A9 (en) 2024-05-23
AR124286A1 (es) 2023-03-15
US20240025988A1 (en) 2024-01-25
CL2023001556A1 (es) 2023-11-10
MX2023006294A (es) 2023-06-13
KR20230098288A (ko) 2023-07-03
EP4255928A1 (en) 2023-10-11
TWI821804B (zh) 2023-11-11
PH12023551170A1 (en) 2024-01-22
WO2022117526A1 (en) 2022-06-09
US20240425581A1 (en) 2024-12-26
AU2021391493B2 (en) 2025-10-30
US12122828B2 (en) 2024-10-22
US20220169717A1 (en) 2022-06-02
TW202237183A (zh) 2022-10-01
CO2023007851A2 (es) 2023-06-30
CA3199648A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
US20230201346A1 (en) Binding molecules specific for il-21 and uses thereof
JP6646100B2 (ja) 抗ｃｘｃｒ３抗体
CA2883821C (en) Il-18 binding molecules
US20240425581A1 (en) IL-7 Binding Proteins and Their Use in Medical Therapy
WO2023227641A1 (en) Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment
HK40031443A (en) Binding molecules specific for il-21 and uses thereof
NZ762893B2 (en) Binding molecules specific for il-21 and uses thereof
BR112016029734B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno deste e uso do mesmo, composição farmacêutica e método para detecção de níveis de expressão de il-21 em uma amostra
NZ725735B2 (en) Binding molecules specific for il-21 and uses thereof
HK1230976A1 (en) Binding molecules specific for il-21 and uses thereof
HK1230976B (en) Binding molecules specific for il-21 and uses thereof

Legal Events

Date Code Title Description
SREP Specification republished
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JAN 2026

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JAN 2026

FGA Letters patent sealed or granted (standard patent)